Meeting
2016 ASCO Annual Meeting
Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study.
Authors
Diane Lauren Reidy
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Diane Lauren Reidy , Matthew H. Kulke , Edward M. Wolin , Simron Singh , Diego Ferone , Beloo Mirakhur , Christine Massien , Aude Houchard , Martyn E. Caplin , Eric Baudin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
2015-004992-62
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS8580)
DOI
10.1200/JCO.2016.34.15_suppl.TPS8580
Abstract #
TPS8580
Poster Bd #
203a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
First Author: Ariela Noy
Poster
2017 ASCO Annual Meeting
A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.
First Author: Yoon-Koo Kang